Wipfli Financial Advisors’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Wipfli Financial Advisors’s Portfolio MRTX Stock Details MRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	$42K	Buy	+600	New	+$44.4K	﹤0.01%	1189

Other funds holding MRTX

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Wipfli Financial Advisors's MRTX Position: Q3 2022 in Review

Wipfli Financial Advisors opened a new position in Mirati Therapeutics, Inc. Common Stock (MRTX) in Q3 2022: 600 shares worth $42K. The stake represents ﹤0.01% of the portfolio and ranks #1189 among its holdings.

243 funds tracked by Wall St. Rank hold MRTX as of Q3 2022.

Wipfli Financial Advisors held 600 shares of Mirati Therapeutics, Inc. Common Stock worth $42K as of Q3 2022.
Mirati Therapeutics, Inc. Common Stock was a new Wipfli Financial Advisors position in Q3 2022.
Mirati Therapeutics, Inc. Common Stock made up ﹤0.01% of Wipfli Financial Advisors's portfolio in Q3 2022, its #1189 holding.
243 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q3 2022.

Based on Wipfli Financial Advisors's 13F filing for Q3 2022, filed 26 Oct 2022.